Literature DB >> 30025620

Predicting the future burden of NAFLD and NASH.

Suzanne E Mahady1, Jacob George2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30025620     DOI： 10.1016/j.jhep.2018.06.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  11 in total

Review 1.  New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.

Authors:  Natalia Pydyn; Katarzyna Miękus; Jolanta Jura; Jerzy Kotlinowski
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

2.  Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis.

Authors:  Davide Povero; Eva M Pinatel; Aleksandra Leszczynska; Nidhi P Goyal; Takahiro Nishio; Jihoon Kim; David Kneiber; Lucas de Araujo Horcel; Akiko Eguchi; Paulina M Ordonez; Tatiana Kisseleva; Ariel E Feldstein
Journal:  JCI Insight       Date:  2019-06-11

Review 3.  Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant.

Authors:  Anchalia Chandrakumaran; Mohammad Shadab Siddiqui
Journal:  Gastroenterol Clin North Am       Date:  2020-03       Impact factor: 3.806

4.  Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA.

Authors:  Alexander L Nguyen; Haesuk Park; Pauline Nguyen; Edward Sheen; Yoona A Kim; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2018-10-16       Impact factor: 3.199

Review 5.  Non-alcoholic fatty liver disease and Atherosclerosis at a crossroad: The overlap of a theory of change and bioinformatics.

Authors:  Guglielmo M Trovato
Journal:  World J Gastrointest Pathophysiol       Date:  2020-05-12

6.  Age, Gender and Geographic Differences in Global Health Burden of Cirrhosis and Liver Cancer due to Nonalcoholic Steatohepatitis.

Authors:  Tianyue Zhang; Jingya Xu; Lingxia Ye; Xiling Lin; Yufeng Xu; Xiaowen Pan; Xifang Weng; Chuyu Ye; Longjiang Fan; Yuezhong Ren; Peng-Fei Shan
Journal:  J Cancer       Date:  2021-03-15       Impact factor: 4.207

7.  Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis.

Authors:  Jingxuan Lian; Jianfang Fu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-24       Impact factor: 5.555

8.  Prevalence of Elevated Alanine Aminotransferase by Diagnostic Criterion, Age, and Gender among Adolescents.

Authors:  Jing Zhang; Zheng-Ying Wang; Jing-Ping Zhang; Hua Zhou; Zan Ding
Journal:  Gastroenterol Res Pract       Date:  2020-01-25       Impact factor: 2.260

9.  Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.

Authors:  Manuel Romero-Gomez; Nandita Kachru; Meritxell Ascanio Zamorano; Josep Darba; Sanatan Shreay
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

Review 10.  Drug Discovery in Liver Disease Using Kinome Profiling.

Authors:  Bingting Yu; Ruslan Mamedov; Gwenny M Fuhler; Maikel P Peppelenbosch
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.